This webinar will address the recent announcement by the Therapeutic Goods Administration (TGA) that medicines containing psilocybin and MDMA will be classified as Schedule 8 (controlled drug) in the Poisons Standard for specific conditions when prescribed by a psychiatrist under the Authorised Prescriber scheme.
Background
From 1 July 2023, the TGA will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression. They will only be able to be prescribed by authorised psychiatrists who have been approved under the Authorised Prescriber scheme and approved by a Human Research Ethics Committee.
